Skip to content

Study · Randomized controlled trial · n = 19 · 2019

2 results

Prehospital exenatide in hyperglycemic stroke-A randomized trial.

Larsson M, Castrén M, Lindström V, von Euler M, Patrone C, Wahlgren N, Nathanson D

Acta neurologica Scandinavica2 Oct 2019Cited by 6 (Europe PMC)

PMID31518433 (opens in a new tab)DOI10.1111/ane.13166 (opens in a new tab)PepBankPUB-31518433
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hyperglycemic stroke patients, exenatide did not significantly change plasma glucose at 4 hours versus standard care.

    In plain wordsIn stroke patients with high glucose, exenatide did not significantly change glucose at 4 hours versus standard care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePlasma glucose at 4 hours
    Study

    n = 19

    Comparator
    Standard care for hyperglycemia
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Plasma glucose at 4 hours
    7.6 mmol/L
    exenatide
    Plasma glucose at 4 hours
    7 mmol/L
    control (standard care)

    Source sentences

    Summary
    No difference was observed in the main outcome of plasma glucose at 4 hours, control vs exenatide (mean, SD); 7.0 ± 1.9 vs 7.6 ± 1.6; P = .56).
    3 context sentences
    Summary · context
    Patients with Face Arm Speech Test ≥1 and glucose ≥8 mmol/L were randomized.
    Summary · context
    Randomized controlled trial comparing exenatide administrated prehospitally with a control group receiving standard care for hyperglycemia.
    Summary · context
    Nineteen patients were randomized, eight received exenatide.
  2. 02HumanRandomized controlled trialSafety outcome

    In the stroke trial, no major adverse events were reported, including in exenatide recipients.

    In plain wordsIn the stroke trial, no major adverse events were reported, including in exenatide recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableMajor adverse events
    Study

    n = 19

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No major adverse events were reported.
    2 context sentences
    Summary · context
    Randomized controlled trial comparing exenatide administrated prehospitally with a control group receiving standard care for hyperglycemia.
    Summary · context
    Nineteen patients were randomized, eight received exenatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.